215 related articles for article (PubMed ID: 38050240)
1. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
Yu Y; Lou Y; Zhu J; Wang X
Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
[TBL] [Abstract][Full Text] [Related]
2. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma.
Pan Y; Zhu Q; Hong T; Cheng J; Tang X
Aging (Albany NY); 2024 May; 16(10):9047-9071. PubMed ID: 38787389
[TBL] [Abstract][Full Text] [Related]
3. A novel PCDscore based on programmed cell death-related genes can effectively predict prognosis and therapy responses of colon adenocarcinoma.
Peng Y; Ouyang C; Wu Y; Ma R; Li H; Li Y; Jing J; Sun L
Comput Biol Med; 2024 Mar; 170():107933. PubMed ID: 38217978
[TBL] [Abstract][Full Text] [Related]
4. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
5. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
Xu X; Wang J
Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
[TBL] [Abstract][Full Text] [Related]
6. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
7. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
Wang L; Wang Q; Li Y; Qi X; Fan X
J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
10. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract][Full Text] [Related]
12. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
13. Exploring the role of CDCA4 in liver hepatocellular carcinoma using bioinformatics analysis and experiments.
Liang C; Long K; Zheng W; Zhong R; Li Z; Zhu S; Gu S; Zhu C; Yang Y
Medicine (Baltimore); 2024 May; 103(18):e38028. PubMed ID: 38701314
[TBL] [Abstract][Full Text] [Related]
14. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
[TBL] [Abstract][Full Text] [Related]
15. Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes.
Wang G; Li J; Zhu L; Zhou Z; Ma Z; Zhang H; Yang Y; Niu Q; Wang X
Discov Oncol; 2023 Aug; 14(1):147. PubMed ID: 37555866
[TBL] [Abstract][Full Text] [Related]
16. Constructing immune and prognostic features associated with ADCP in hepatocellular carcinoma and pan-cancer based on scRNA-seq and bulk RNA-seq.
Zhang Z; Li Y; Quan Z; Li Y; Zhu L; Sun S; Chen X
Front Immunol; 2024; 15():1397541. PubMed ID: 38774870
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of palmitoylation metabolism-related signature for liver hepatocellular carcinoma.
Feng R; Cheng D; Chen X; Yang L; Wu H
Biochem Biophys Res Commun; 2024 Jan; 692():149325. PubMed ID: 38056161
[TBL] [Abstract][Full Text] [Related]
18. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
Liu Z; Zhao P
J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
[TBL] [Abstract][Full Text] [Related]
20. Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma.
Ji Z; Zhang C; Yuan J; He Q; Zhang X; Yang D; Xu N; Chu J
PLoS One; 2024; 19(4):e0298775. PubMed ID: 38662757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]